Discover MAYZENT®

Once-daily MAYZENT is the first and
only pill studied and proven in active
secondary progressive multiple
sclerosis (SPMS). Keep reading to
learn more, and don't forget to ask
your doctor about MAYZENT.

Slow down MS disability progression with MAYZENT
Slow down MS disability progression with MAYZENT

Discover MAYZENT®

Once-daily MAYZENT is the first and only pill studied and proven in active secondary progressive multiple sclerosis (SPMS). Keep reading to learn more, and don't forget to ask your doctor about MAYZENT.

Slow down disability progression and
hold on to more moments with MAYZENT

In a 3-year clinical trial, MAYZENT was proven to significantly delay disability progression
in people with SPMS. The length of time people stayed in the clinical trial varied
(median was 21 months with a range of 1 day to 37 months).

See the results below and discover what's possible.

SLOWING DOWN
DISABILITY PROGRESSION

ADDITIONAL
RESULTS

Overall clinical trial results for 3-month confirmed disability progression:

Nearly 3 out of 4 people taking MAYZENT showed no confirmed disability progression
Lower chance of disability progression

Nearly 3 out of 4 people taking MAYZENT showed no confirmed disability progression*

People taking MAYZENT had a 21% lower chance of disability progression compared to those taking placebo

*Nearly 3 out of 4 is 74%, compared to 68% taking placebo.

The effect of MAYZENT was significant in patients with active SPMS
and not considered significant in patients with nonactive SPMS.

Other results from the MAYZENT clinical trial

No significant difference between MAYZENT
and placebo in a timed 25-foot walk test

The timed 25-foot walk is a test that measures how quickly someone can walk 25 feet. The score is the average of two of these tests.

Because there was no significant difference in the results above, it can't be determined by this clinical trial whether the following results were due to treatment with MAYZENT or if they happened by chance

T2 lesion volume

The change in T2 lesion* volume from baseline, or starting point, for people taking MAYZENT was 184 mm3 vs 879 mm3 for people taking placebo.

Annual relapse rate (ARR)

People taking MAYZENT reduced their ARR by 55% compared to those taking placebo.

*New or enlarging T2 lesions, also called plaques, are associated with MS progression.
ARR is the average number of relapses someone has in 1 year.

SLOWING DOWN
DISABILITY PROGRESSION

ADDITIONAL
RESULTS

Overall clinical trial results for
3-month confirmed disability progression:

Nearly 3 out of 4 people taking MAYZENT showed no confirmed disability progression

Nearly 3 out of 4 people taking MAYZENT showed no confirmed disability progression*

*Nearly 3 out of 4 is 74%, compared to 68% taking placebo.

Lower chance of disability progression

People taking MAYZENT had a 21% lower chance of disability progression compared to those taking placebo

The effect of MAYZENT was significant in patients with active SPMS and not considered significant in patients with nonactive SPMS.

Other results from the
MAYZENT clinical trial

No significant difference between MAYZENT and placebo in a timed 25-foot walk test

The timed 25-foot walk is a test that measures how quickly someone can walk 25 feet. The score is the average of two of these tests.

Because there was no significant difference in the results above, it can't be determined by this clinical trial whether the following results were due to treatment with MAYZENT or if they happened by chance

reduced growth of T2

T2 lesion volume

The change in T2 lesion* volume from baseline, or starting point, for people taking MAYZENT was 184 mm3 vs 879 mm3 for people taking placebo.

annual relapse rate

Annual relapse rate (ARR)

People taking MAYZENT reduced their ARR by 55% compared to those taking placebo.

*New or enlarging T2 lesions, also called plaques, are associated with MS progression.
ARR is the average number of relapses someone has in 1 year.

Talk to your doctor Talk to your doctor

The MAYZENT clinical trial was the largest of its
kind and included a wide range of people with SPMS

The clinical trial lasted up to 3 years, and people stayed in it for a
median of nearly 2 years (21 months).‡ Because people with SPMS are not all alike,
participants varied in age, levels of disability, and in other ways.

Take a closer look at the 1651 participants

Take a closer look at the
1651 participants

MAYZENT trial

Average time
since diagnosis:

13 years

13 years

Wide range
of ages:

21-61 years

21-61 years

Average age:

48 years

48 years

78%

78%

had previously been
on an MS treatment

MAYZENT trial

56%

56%

used a
walking aid

44%

44%

did not use a
walking aid

60%

60%

were female

40%

40%

were male

Clinical trial included people with active and nonactive SPMS.

Clinical trial included people with
active and nonactive SPMS.

The trial was designed to measure the length of time to disability progression. Before the start
of the clinical trial, researchers used different calculations to establish that the trial would
be stopped if a specific number of people experienced disability progression. Because of this, not
all patients stayed in the clinical trial for 3 years.

Slow down MS disability progression with MAYZENT
Slow down MS disability progression with MAYZENT
Slow down MS disability progression with MAYZENT

Know your MS

Create a personalized discussion guide to help you talk to your doctor about MAYZENT and active SPMS.

Stay informed

Get information about MAYZENT and active SPMS delivered right to you.

Thanks!

Your e-mail has been sent.

Share this site with your doctor to let them know
you would like to discuss MAYZENT at your next visit

Oops! We need this information.

Oops! We need this information.

Oops! We need this information.

Oops! We need this information.

Oops! We need this information.

Oops! We need this information.

expand VIEW MORE
collapse VIEW LESS

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

Do not take MAYZENT if you:

  • have a CYP2C9*3/*3 genotype. Before starting treatment with MAYZENT, your CYP2C9 genotype should be determined by your health care provider. Ask your health care provider if you are not sure.

  • have had a heart attack, chest pain called unstable angina, stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months

What is MAYZENT® (siponimod) tablets?

MAYZENT is a prescription medicine that is used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

It is not known if MAYZENT is safe and effective in children.

  • have certain types of heart block or irregular or abnormal heartbeat (arrhythmia), unless you have a pacemaker

MAYZENT may cause serious side effects, including:

  1. Slow heart rate (bradycardia or bradyarrhythmia) when you start taking MAYZENT. MAYZENT can cause your heart rate to slow down, especially after you take your first dose. You should have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of MAYZENT.

    During the initial updosing period (4 days for the 1-mg daily dose or 5 days for the 2-mg daily dose), if you miss 1 or more doses of MAYZENT, you need to restart the updosing. Call your health care provider if you miss a dose of MAYZENT.

  2. Infections. MAYZENT can increase your risk of serious infections that can be life-threatening and cause death. MAYZENT lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 to 4 weeks of stopping treatment. Your health care provider should review a recent blood test of your white blood cells before you start taking MAYZENT.

    Call your health care provider right away if you have any of these symptoms of an infection during treatment with MAYZENT and for 3 to 4 weeks after your last dose of MAYZENT:

    • fever

    • tiredness

    • body aches

    • chills

    • nausea

    • vomiting

    • headache with fever, neck stiffness, sensitivity to light, nausea, confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

  3. A problem with your vision called macular edema. Macular edema can cause some of the same vision symptoms as a multiple sclerosis (MS) attack (optic neuritis). You may not notice any symptoms with macular edema. If macular edema happens, it usually starts in the first 1 to 4 months after you start taking MAYZENT. Your health care provider should test your vision before you start taking MAYZENT and any time you notice vision changes during treatment with MAYZENT. Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis.

    Call your health care provider right away if you have any of the following: blurriness or shadows in the center of your vision, a blind spot in the center of your vision, sensitivity to light, or unusually colored (tinted) vision.

Before taking MAYZENT, tell your health care provider about all of your medical conditions, including if you:

  • have an irregular or abnormal heartbeat

  • have a history of stroke or other diseases related to blood vessels in the brain

  • have breathing problems, including during your sleep

  • have a fever or infection, or you are unable to fight infections due to a disease or are taking medicines that lower your immune system. Tell your health care provider if you have had chickenpox or have received the vaccine for chickenpox. Your health care provider may do a blood test for chickenpox virus. You may need to get the full course of vaccine for chickenpox and then wait 1 month before you start taking MAYZENT.

  • have slow heart rate

  • have liver problems

  • have diabetes

  • have eye problems, especially an inflammation of the eye called uveitis

  • have high blood pressure

  • are pregnant or plan to become pregnant. MAYZENT may harm your unborn baby. Talk to your health care provider right away if you become pregnant while taking MAYZENT or if you become pregnant within 10 days after you stop taking MAYZENT.

    • If you are a woman who can become pregnant, you should use effective birth control during your treatment with MAYZENT and for at least 10 days after you stop taking MAYZENT.

  • are breastfeeding or plan to breastfeed. It is not known if MAYZENT passes into your breast milk. Talk to your health care provider about the best way to feed your baby if you take MAYZENT.

Tell your health care provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Especially tell your health care provider if you take medicines to control your heart rhythm (anti-arrhythmics), or blood pressure (antihypertensives), or heart beat (such as calcium channel blockers or beta-blockers); take medicines that affect your immune system, such as beta-interferon or glatiramer acetate, or any of these medicines that you took in the past.

Tell your health care provider if you have recently received a live vaccine. You should avoid receiving live vaccines during treatment with MAYZENT. MAYZENT should be stopped 1 week before and for 4 weeks after receiving a live vaccine. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Vaccines may not work as well when given during treatment with MAYZENT.

MAYZENT may cause possible side effects, including:

  • increased blood pressure. Your health care provider should check your blood pressure during treatment with MAYZENT.

  • liver problems. MAYZENT may cause liver problems. Your health care provider should do blood tests to check your liver before you start taking MAYZENT. Call your health care provider right away if you have any of the following symptoms of liver problems:

    • nausea

    • vomiting

    • stomach pain

    • tiredness

    • loss of appetite

    • your skin or the whites of your eyes turn yellow

    • dark urine

  • breathing problems. Some people who take MAYZENT have shortness of breath. Call your health care provider right away if you have new or worsening breathing problems.

  • swelling and narrowing of the blood vessels in your brain. A condition called PRES (Posterior Reversible Encephalopathy Syndrome) has happened with drugs in the same class. Symptoms of PRES usually get better when you stop taking MAYZENT. However, if left untreated, it may lead to a stroke. Call your health care provider right away if you have any of the following symptoms: sudden severe headache, sudden confusion, sudden loss of vision or other changes in vision, or seizure.

  • severe worsening of multiple sclerosis after stopping MAYZENT. When MAYZENT is stopped, symptoms of MS may return and become worse compared to before or during treatment. Always talk to your doctor before you stop taking MAYZENT for any reason. Tell your health care provider if you have worsening symptoms of MS after stopping MAYZENT.

The most common side effects of MAYZENT include: headache, high blood pressure (hypertension), and abnormal liver tests.

These are not all of the possible side effects of MAYZENT. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

What is MAYZENT® (siponimod) tablets?

MAYZENT is a prescription medicine that is used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

It is not known if MAYZENT is safe and effective in children.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.